Loading company details...
Beta
Latest Form 4 (Sep 2, 2026): Julian Adams (Director): Grant/Award of 21,750 shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Julian Adams | Grant/Award | 21,750 | n/a |
| Sep 2, 2026 | Carol Gail Ashe | Grant/Award | 21,750 | n/a |
| Sep 2, 2026 | Yekaterina Chudnovsky | Grant/Award | 21,750 | n/a |
| Sep 2, 2026 | Allen Nissenson | Grant/Award | 21,750 | n/a |
| Sep 2, 2026 | Robert R. Ruffolo | Grant/Award | 21,750 | n/a |
| Sep 2, 2026 | Karen J. Wilson | Grant/Award | 21,750 | n/a |
| Sep 2, 2026 | Jay Venkatesan | Grant/Award | 21,750 | n/a |
| Jul 17, 2026 | Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer | Grant/Award | 64,643 | n/a |
| Jul 17, 2026 | Peter DeMuth, Chief Scientific Officer | Grant/Award | 52,832 | n/a |
| Jul 17, 2026 | Preetam Shah, Chief Strategy and Financial Officer | Grant/Award | 60,833 | n/a |